I can’t talk about the DSMC, but I have met with FDA
I can’t talk about the DSMC, but I have met with FDA policy makers a couple of times. My biggest takeaway was that their egos and arrogance know no bounds. They are a group that believes their authority over drug policy and approvals anoint them as having few peers on medical issues. They stare across the table with the attitude that their interlocutors are damn lucky to be able to meet with the FDA . So we don’t know how the dosage variance was presented by our lowly West Coast startup biopharma, But I can imagine an attitude of how dare you question our decisions. I am sure that when Merck comes to the meeting they bring a prestigious staff who have probably met with the FDA frequently.
On top of this, the FDA like many federal government agencies put new or changed regulations to the public for a public comment period. I would suggest that Merck has a group that watches and comments on the changed regulations to make sure they are favorable. (Merck being an example).
So I don’t support the dark conspiracies but would suggest a conspiracy of arrogance and of entrenched bureaucratics.
On a bit off topic, I must say that I am now less surprised by the vehemence of the FDA hit piece on our CD12 results. Seeing the total shambles of the Amarex submission on HIV BLA, the FDA must have been pissed off at the campaign for an EUA for Leronlimab last winter especially when they had rendered their verdict and we didn’t really hit end points except on a subset.
All IMHO
17
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Revolutionizing Security with Drone Technology Titan Protection and Consulting recently heralded a significant achievement in the field of security technology. The company has introduced a pioneering deployment of self-docking, remote-piloted security drones, which successfully thwarted an attempted theft at a dealership in Kansas City. This event not only underscores...
Continue Reading
Financial Stress — The Silent Productivity Killer Down in the trenches of nine-to-five, it’s money that keeps stealing workers' peace of mind. The TELUS Mental Health Index shines a glaring spotlight on this, revealing that 58% of U.S. workers are most stressed by living costs. Now, that's a kicker when stacking it next to retirement or emergency savings. Those take...
Continue Reading
Equinor Makes a New Oil Discovery in the North Sea Equinor ASA (NYSE: EQNR) is experiencing a positive surge in its stock prices today, following the recent discovery of a new oil field located 17 kilometers from the Troll field in the North Sea. This exciting discovery has estimated reserves that could range between 2 and 12 million barrels of oil equivalent, which...
Continue Reading
Game-Changing Patent for Xact Labs Xact Laboratories just nabbed a new patent—number 12,640,242 if you're keeping track. This isn't just a shiny badge for show; it's core to their play in the big leagues of precision medicine, clinching their spot as a frontrunner in genetic data integration. The endgame here? Tighten that grip on the precision medicine field, and turn...
Continue Reading
Understanding Cleveland-Cliffs' Options Activity Recently, significant investments have been noted in Cleveland-Cliffs, indicating a bullish sentiment among traders. Investors are closely analyzing the options activity for Cleveland-Cliffs (NYSE: CLF), which has revealed a series of intriguing trades. An Overview of Recent Trades Upon reviewing recent options transactions...
Continue Reading